The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Males and females ≥ 18 years of age.
Life expectancy of ≥ 3 months.
Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2.
Histopathologically confirmed diagnosis of CLL (medical record is acceptable), as per the World Health Organization 2016 classification.
Active second malignancy unless in remission with a life expectancy of > 2 years and with documented Sponsor approval.
Active malignancy other than CLL requiring systemic therapy (exceptions may be granted following a discussion with the Sponsor Medical Monitor).
Have high-risk CLL TP53 mutations and 17P deletion.
History of Grade ≥ 3 rhabdomyolysis without complete recovery.